Literature DB >> 15719129

Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat.

Xiao-Chuan Wang1, Jing Zhang, Xian Yu, Liu Han, Zhen-Tao Zhou, Yao Zhang, Jian-Zhi Wang.   

Abstract

Hyperphosphorylated microtubule-associated protein tau is the major protein component of neurofibrillary tangles in the brain of patients with Alzheimer's disease (AD). Until now, there is no effective cure to arrest this hyperphosphorylation. The present study was designed to explore the in vivo preventive effect of melatonin on Alzheimer-like tau hyperphosphorylation. Isoproterenol, a beta-receptor agonist, was used to induce tau hyperphosphorylation, and for preventive effect of melatonin, the rats were injected intraperitoneally with melatonin for 5 d before hippocampi infusion of isoproterenol. The level of tau phosphorylation was detected by Western blot and immunohistochemistry using sites specific antibodies (PHF-1 and Tau-1), and it was normalized by non-phosphorylation dependent total tau antibody (111e). The results by Western blot showed that the immunoreaction of tau at PHF-1 epitope was enhanced, and the reaction at Tau-1 epitope was weakened significantly at 48 h after injection of isoproterenol, suggesting hyperphosphorylation of tau at Ser 396/Ser 404 (PHF-1) and Ser199/Ser 202 (Tau-1) sites. Similar results were observed by immunohistochemistry staining, in which hyperphosphorylated tau was mainly detected in mossy fibers of hippocampal CA3 region. Pre-injection of rats with melatonin intraperitoneally arrested effectively the isoproterenol-induced tau hyperphosphorylation at both Tau-1 and PHF-1 sites, implying the preventive effect of melatonin in Alzheimer-like tau hyperphosphorylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15719129

Source DB:  PubMed          Journal:  Sheng Li Xue Bao        ISSN: 0371-0874


  17 in total

Review 1.  Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.

Authors:  Neeraj Joshi; Joyshree Biswas; C Nath; Sarika Singh
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

Review 2.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

Review 3.  Pharmacological Effects of Melatonin as Neuroprotectant in Rodent Model: A Review on the Current Biological Evidence.

Authors:  Hui Ying Tan; Khuen Yen Ng; Rhun Yian Koh; Soi Moi Chye
Journal:  Cell Mol Neurobiol       Date:  2019-08-21       Impact factor: 5.046

4.  Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease.

Authors:  Hongwen He; Weiguo Dong; Fang Huang
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

5.  A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.

Authors:  Michele Fornaro; Davide Prestia; Salvatore Colicchio; Giulio Perugi
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

Review 6.  The antiapoptotic activity of melatonin in neurodegenerative diseases.

Authors:  Xin Wang
Journal:  CNS Neurosci Ther       Date:  2009-10-10       Impact factor: 5.243

7.  Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.

Authors:  Venkatramanujam Srinivasan; Charanjit Kaur; Seithikurippu Pandi-Perumal; Gregory M Brown; Daniel P Cardinali
Journal:  Int J Alzheimers Dis       Date:  2010-12-08

8.  Antiinflammatory activity of melatonin in central nervous system.

Authors:  Emanuela Esposito; Salvatore Cuzzocrea
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

Review 9.  Antioxidant therapies for Alzheimer's disease.

Authors:  Ye Feng; Xiaochuan Wang
Journal:  Oxid Med Cell Longev       Date:  2012-07-25       Impact factor: 6.543

10.  Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau.

Authors:  Yang Hong-Qi; Sun Zhi-Kun; Chen Sheng-Di
Journal:  Transl Neurodegener       Date:  2012-10-30       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.